drugset / Trial / NCT00857324
Study of Vorinostat Plus Melphalan and Prednisone (Zmp) in Advanced, Refractory Multiple Myeloma Patients
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine whether the association of ZMP is safe and provides benefits in patients with relapsed/refractory MM.
Timeline
- Start
- 2009-03
- Primary completion
- 2012-03
- Completion
- 2017-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Vorinostat | Small molecule | 100 mg | — |
| Subject | Vorinostat | Small molecule | 200 mg | — |
| Subject | Vorinostat | Small molecule | 300 mg | — |
| Subject | Vorinostat | Small molecule | 400 mg | — |